JP2013177372A - 非水性液体組成物 - Google Patents

非水性液体組成物 Download PDF

Info

Publication number
JP2013177372A
JP2013177372A JP2013015164A JP2013015164A JP2013177372A JP 2013177372 A JP2013177372 A JP 2013177372A JP 2013015164 A JP2013015164 A JP 2013015164A JP 2013015164 A JP2013015164 A JP 2013015164A JP 2013177372 A JP2013177372 A JP 2013177372A
Authority
JP
Japan
Prior art keywords
aqueous liquid
liquid composition
drug
range
tocopherol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013015164A
Other languages
English (en)
Japanese (ja)
Inventor
Kazuto Yamada
和人 山田
Arto Urtti
ウルチ アルト
Mechthild Burmester
ブルメスター メッキチルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to JP2013015164A priority Critical patent/JP2013177372A/ja
Publication of JP2013177372A publication Critical patent/JP2013177372A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2013015164A 2012-01-31 2013-01-30 非水性液体組成物 Pending JP2013177372A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013015164A JP2013177372A (ja) 2012-01-31 2013-01-30 非水性液体組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012018062 2012-01-31
JP2012018062 2012-01-31
JP2013015164A JP2013177372A (ja) 2012-01-31 2013-01-30 非水性液体組成物

Publications (1)

Publication Number Publication Date
JP2013177372A true JP2013177372A (ja) 2013-09-09

Family

ID=48905235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013015164A Pending JP2013177372A (ja) 2012-01-31 2013-01-30 非水性液体組成物

Country Status (12)

Country Link
US (1) US20150011518A1 (cg-RX-API-DMAC7.html)
EP (1) EP2810657B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013177372A (cg-RX-API-DMAC7.html)
KR (1) KR20150000874A (cg-RX-API-DMAC7.html)
CN (1) CN104080478A (cg-RX-API-DMAC7.html)
CA (1) CA2861261A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491453A1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN06911A (cg-RX-API-DMAC7.html)
PH (1) PH12014501689A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201606271RA (cg-RX-API-DMAC7.html)
TW (1) TW201336526A (cg-RX-API-DMAC7.html)
WO (1) WO2013115201A1 (cg-RX-API-DMAC7.html)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527869A (ja) * 2003-11-17 2007-10-04 アルザ・コーポレーシヨン 両親媒性分子を懸濁ビヒクルとして含んでなる組成物および投薬形態
JP2008501676A (ja) * 2004-06-04 2008-01-24 カムルス エービー 流体デポ製剤
JP2008526932A (ja) * 2005-01-14 2008-07-24 カムルス エービー 局所用生体付着性製剤
JP2008526933A (ja) * 2005-01-14 2008-07-24 カムルス エービー ソマトスタチン類似体製剤
JP2008528463A (ja) * 2005-01-21 2008-07-31 カムルス エービー 医薬脂質組成物
JP2008542437A (ja) * 2005-06-06 2008-11-27 カムルス エービー Glp−1類似体製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
AU6919598A (en) * 1997-04-17 1998-11-13 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
JP4496406B2 (ja) 2003-03-07 2010-07-07 参天製薬株式会社 4−ピリジルアルキルチオ基を置換基として有する新規化合物
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
JP4626353B2 (ja) 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した4−ピリジルアルキルチオ基を有する新規環式化合物
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
JP4585978B2 (ja) 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物
JP4825636B2 (ja) 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
JP5054996B2 (ja) 2006-03-14 2012-10-24 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2,3,4−テトラヒドロキノキサリン誘導体
KR20090086539A (ko) 2006-11-14 2009-08-13 산텐 세이야꾸 가부시키가이샤 (치환 페닐 또는 치환 복소환) 카르보닐옥시 저급 알킬기와 에스테르 구조를 도입한 페닐기를 치환기로서 갖는 신규 1,2-디히드로퀴놀린 유도체
EP2128156A4 (en) 2007-01-29 2011-05-18 Santen Pharmaceutical Co Ltd NEW OXADIAZOL DERIVATIVES AND THIADIAZONE DERIVATIVES WITH THE NEOVASCULARIZATION HEMMENDER EFFECT
EP2151436B1 (en) 2007-05-29 2013-04-24 Santen Pharmaceutical Co., Ltd Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2009035068A1 (ja) 2007-09-13 2009-03-19 Santen Pharmaceutical Co., Ltd. 新規1,3,3-トリメチル-7-フェニル-3,4-ジヒドロ-1h-キノキサリン-2-オン誘導体
AU2010271746B2 (en) 2009-07-17 2014-07-03 Santen Pharmaceutical Co., Ltd. 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007527869A (ja) * 2003-11-17 2007-10-04 アルザ・コーポレーシヨン 両親媒性分子を懸濁ビヒクルとして含んでなる組成物および投薬形態
JP2008501676A (ja) * 2004-06-04 2008-01-24 カムルス エービー 流体デポ製剤
JP2008526932A (ja) * 2005-01-14 2008-07-24 カムルス エービー 局所用生体付着性製剤
JP2008526933A (ja) * 2005-01-14 2008-07-24 カムルス エービー ソマトスタチン類似体製剤
JP2008528463A (ja) * 2005-01-21 2008-07-31 カムルス エービー 医薬脂質組成物
JP2008542437A (ja) * 2005-06-06 2008-11-27 カムルス エービー Glp−1類似体製剤

Also Published As

Publication number Publication date
PH12014501689A1 (en) 2014-10-20
EP2810657A4 (en) 2015-07-29
US20150011518A1 (en) 2015-01-08
EA201491453A1 (ru) 2014-12-30
WO2013115201A1 (ja) 2013-08-08
IN2014DN06911A (cg-RX-API-DMAC7.html) 2015-05-15
EP2810657B1 (en) 2016-09-21
CA2861261A1 (en) 2013-08-08
SG10201606271RA (en) 2016-09-29
SG11201404230QA (en) 2014-10-30
KR20150000874A (ko) 2015-01-05
CN104080478A (zh) 2014-10-01
TW201336526A (zh) 2013-09-16
EP2810657A1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
Boyd et al. Hexosomes formed from glycerate surfactants—Formulation as a colloidal carrier for irinotecan
EP3843704B1 (en) Emulsion formulations of multikinase inhibitors
AU2010221438B2 (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
AU2017228608C1 (en) Injectable preparation
CA2908571C (en) Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives
JP2016529308A (ja) フルベストラント組成物
JP2015520230A (ja) アキシチニブを含んでいる眼科用局所医薬組成物
KR102365008B1 (ko) 디쿠아포솔을 포함하는 점안 조성물
KR101996597B1 (ko) 두타스테리드와 타다라필을 용해시킨 경구용 캡슐 제형의 복합제제
JP6185725B2 (ja) 水性医薬組成物
JP2011500542A (ja) 新規タキソイドに基づく組成物
Khopade et al. Low dose ophthalmic solution of difluprednate for the management of pain and inflammation
WO2013115201A1 (ja) 非水性液体組成物
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
Salimi et al. Ocular delivery of ketorolac tromethamine using microemulsion as a vehicle: Design, evaluation, and transcorneal permeation
CN101912362B (zh) 一种替尼泊苷静脉注射用脂肪乳预乳化浓缩液及其制备方法
EP4447930A1 (en) Stable formulations of shr0302
JP5092266B2 (ja) 眼科用剤
JP5223307B2 (ja) 坐剤
JP2007016024A (ja) ロフルミラスト点眼液
CA2866810A1 (en) Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
KR100509433B1 (ko) S(+)-이부프로펜의 연질캅셀제 조성물 및 그의 제조방법
Rezae et al. Preparation and In Vitro Characterization of Triamcinolone Acetonide-Loaded Lipid Liquid Crystal Nanocarriers for Ocular Delivery
TW202237137A (zh) 含戊酸倍他米松(betamethasone valerate)之軟膏劑組成物
JP2016104709A (ja) シスチン誘導体を含有する非水性注射剤及びデポ形成方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170704